Abstract
Advances in surgical procedures, compatibility tests and development of immunosuppressive drugs have helped to increase allograft survival. However, acute rejection and chronic graft dysfunctions still remain as barriers to be overcome. In addition, obesity has emerged as a new risk factor for rejection and graft dysfunction via several immunological effector mechanisms. Sirtuin 1 (Sirt1)…